The Cooper Companies Inc (COO) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...
CooperVision Revenue: $670 million, up 5% or 7% organically.
CooperSurgical Revenue: $333 million, up 8% or 7% organically.
Non-GAAP Earnings: $0.96, up 14% year-over-year.
Gross Margin: 68%, up from 67.3%.
Operating Margin: 24.9%, with operating income up 11%.
Free Cash Flow: $18 million, with CapEx of $78 million.
Net Debt: Increased slightly to $2.47 billion.
Share Repurchase: Approximately 537,000 shares for $40.6 million.
Revenue Guidance: $4.11 billion to $4.15 billion for fiscal 2025, up 5.5% to 6.5%.
Non-GAAP EPS Guidance: $4.05 to $4.11, growth of 10% to 11.5% year-over-year.
Free Cash Flow Guidance: $350 million to $400 million for fiscal 2025.
Warning! GuruFocus has detected 2 Warning Sign with COO.
Release Date: May 29, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
The Cooper Companies Inc (NASDAQ:COO) reported a solid quarter with consolidated organic revenue growth of 7%, driven by double-digit growth in daily silicone hydrogel lenses and the office and surgical portfolio.
Margins improved significantly, with non-GAAP earnings up 14% year-over-year, demonstrating operational improvements and OpEx leverage.
The myopia management portfolio grew 19%, with MiSight up 35%, indicating strong demand and successful implementation of a new pricing model.
CooperSurgical reported revenues of $333 million, up 8% or 7% organically, driven by success in surgical medical devices and labor and delivery portfolio.
The company raised its revenue guidance at the midpoint, reflecting solid Q2 performance and positive impact from updated currency rates.
The Cooper Companies Inc (NASDAQ:COO) is facing a more complex global operating environment, with pressures from channel inventory and market growth assumptions.
Fertility revenues were softer than expected, particularly in Asia Pac, due to market softness and fertility clinics managing cash tighter.
The company reduced its market growth expectations for contact lenses and fertility, reflecting a more conservative outlook.
There is ongoing pressure from tariffs, with an expected negative impact of roughly $4 million to cost of goods this year.
The company anticipates a mid-teens decline in PARAGARD sales in fiscal Q3, following channel fill-driven growth in the first half of the year.
Q: Can you provide insights into the contact lens market dynamics, particularly regarding channel inventory and consumer behavior? A: Albert White, President and CEO, explained that channel inventory fluctuations are impacting reported growth rates. Consumers are purchasing smaller supplies, such as three-month instead of twelve-month supplies, which affects revenue despite strong fitting activity. This trend is expected to continue, putting pressure on inventory levels throughout the year.
Q: What factors contributed to the lowered market growth assumption for Vision Care this year? A: Albert White noted that the market is returning to its historical growth range of 4% to 6%, down from the post-COVID highs. The adjustment reflects general market softness rather than specific issues, with pricing remaining sound and fitting activity still robust.
Q: How is the fertility market performing, and what are the expectations moving forward? A: Albert White highlighted that fertility growth was softer than expected, particularly in Asia Pacific due to market softness and consumer pressure. The industry is expected to grow in the low single digits this year, with some improvement anticipated in the latter half of the year.
Q: Can you elaborate on the impact of tariffs and how Cooper Companies plans to mitigate them? A: Brian Andrews, CFO, stated that tariffs are expected to negatively impact costs by approximately $4 million this year. The company is evaluating mitigation strategies, including potential price increases and adjustments to supply chain flows, to offset the impact.
Q: What is driving the decision to implement a free trial program for MiSight, and how does it affect growth expectations? A: Albert White explained that the free trial program aims to reduce initial fitting barriers for MiSight, as the upfront cost is not the primary barrier. The program is expected to boost fitting activity and accelerate growth, with MiSight projected to achieve over 40% growth in Q4.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
AeroVironment, Inc. (AVAV) Has A Good Gun, Says Jim Cramer
We recently published . AeroVironment, Inc. (NASDAQ:AVAV) is one of the stocks Jim Cramer recently discussed. AeroVironment, Inc. (NASDAQ:AVAV) is a defense contractor that operates primarily in the uncrewed aerial vehicles (UAV) market. Also called drones, this is one of the hottest segments of the global defense industry. In this show, Cramer commented on the growing use of drones and pointed out that a large part of the Pentagon's costs are driven by fighter jet and bomber pilots. The CNBC TV host explained that triple redundancies in such systems drove up costs, and drones might help in reducing the costs and keeping military personnel safe from the risk of shootdowns. As for AeroVironment, Inc. (NASDAQ:AVAV), he outlined a cost-effective weapon to shoot drones: 'Also Wahid Nawabi was on Mad Money. Now he is the CEO of Aerovironment. And they have a gun that shoots 'em down. And it's a couple of pennies. So that's the hope.' Copyright: zabelin / 123RF Stock Photo Previously, the CNBC host discussed AeroVironment, Inc. (NASDAQ:AVAV)'s share price performance in an idea-driven market: 'We are in an idea-driven market and in an idea-driven market I go out with AeroVironment at 190 and then it goes to 290 because I mentioned it in the Mad Dash and then they're able to do a financing.' While we acknowledge the potential of AVAV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
TransMedics Sees Its Earnings Soar
Key Points In its latest quarter, TransMedics reported solid gains in revenue and saw net income nearly triple from year-ago levels. TransMedics increased its full-year 2025 sales outlook. Co-founder/CEO Waleed Hassanein said that TransMedics remains on pace to achieve its long-term goals in the next several years. 10 stocks we like better than TransMedics Group › Here's our initial take on TransMedics' (NASDAQ: TMDX) second-quarter financial report. Key Metrics Metric Q2 2024 Q2 2025 Change vs. Expectations Total revenue $114.3 million $157.4 million 38% Beat Earnings per share $0.35 $0.92 163% Beat Gross margin 61% 61% unchanged n/a Operating expenses $56.8 million $60 million 6% n/a TransMedics Is Becoming a Profit-Making Machine TransMedics reported second-quarter financial results that were considerably better than most investors had anticipated. On the sales front, gains of 38% to $157 million were healthily higher than projected, as the organ transplant specialist reported particularly strong gains in utilization of TransMedics' Organ Care System (OCS) for liver and heart transplant procedures. Gross margin stayed stable at 61%, reflecting disciplined cost controls in production of TransMedics' groundbreaking medical devices. Equally important, though, was the effort that TransMedics made to keep costs in check. Operating expenses were up just 6% in the quarter. That allowed profits to jump to nearly $35 million for the quarter, up from just over $12 million in the year-earlier period. The excellent financial performance has allowed TransMedics to accumulate a healthy cash hoard that now exceeds $400 million in value. Investors were also pleased that TransMedics increased its guidance for the full 2025 year. The organ transplant specialist now expects its sales for the year to come in between $585 million and $605 million. That's up $20 million from its previous guidance range. Immediate Market Reaction Investors celebrated the news, and TransMedics stock was up more than 8% in after-hours trading 30 minutes after the release of its quarterly report. Most had expected solid performance from TransMedics, but the size of the company's growth came as a shock to many, particularly on its bottom line. The move higher helped to offset some of the downward pressure that the stock has fought against over much of the past year. With shares still down roughly a third from their highs last summer, TransMedics has more room to recover if it can generate some positive momentum. What to Watch Co-founder/CEO Waleed Hassanein gave an optimistic view on TransMedics' long-term outlook, saying that the company remains on track to surpass its 10,000-transplant target during 2028. That's a bold goal, but with the company making strategic investments to support its expansion efforts, TransMedics looks like it could keep enjoying impressive growth for years to come. Helpful Resources Full earnings report Investor relations page Do the experts think TransMedics Group is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did TransMedics Group make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,039% vs. just 182% for the S&P — that is beating the market by 856.77%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $630,291!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,791!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 TransMedics Sees Its Earnings Soar was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Regeneron (REGN) Q2 Earnings: What To Expect
Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here's what investors should know. Regeneron missed analysts' revenue expectations by 6.1% last quarter, reporting revenues of $3.03 billion, down 3.7% year on year. It was a disappointing quarter for the company, with a miss of analysts' EPS estimates. Is Regeneron a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Regeneron's revenue to decline 6.9% year on year to $3.30 billion, a reversal from the 12.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $8.43 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 13 downward revisions over the last 30 days (we track 14 analysts). Regeneron has missed Wall Street's revenue estimates twice over the last two years. Looking at Regeneron's peers in the biotechnology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Incyte delivered year-on-year revenue growth of 16.5%, beating analysts' expectations by 5.5%, and United Therapeutics reported revenues up 11.7%, falling short of estimates by 0.5%. Incyte traded up 10.5% following the results. Read our full analysis of Incyte's results here and United Therapeutics's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the biotechnology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.9% on average over the last month. Regeneron is up 3% during the same time and is heading into earnings with an average analyst price target of $721.52 (compared to the current share price of $550.97). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
